Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder

Overview of attention for article published in Frontiers in immunology, July 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 17 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Tocilizumab for Neuromyelitis Optica Spectrum Disorder

Cited by Canadian Agency for Drugs and Technologies in Health on 20 Mar 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.